Thrombin topical (recombinant) - Biologic Drug Details

Summary for thrombin topical (recombinant)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for thrombin topical (recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for thrombin topical (recombinant) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2012-12-30	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2015-06-05	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2015-06-05	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2028-06-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for thrombin topical (recombinant) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for thrombin topical (recombinant)

Country	Patent Number	Estimated Expiration
Canada	2687968
World Intellectual Property Organization (WIPO)	2008157304
European Patent Office	2167041
Israel	202306
Japan	2010529997
Spain	2397234
Australia	2008266094

Market Dynamics and Financial Trajectory for Recombinant Thrombin Topical

Last updated: March 6, 2026

How large is the current market for recombinant thrombin topical?

The global market for recombinant thrombin topical products is estimated at approximately USD 150 million in 2022. Growth is driven primarily by surgical and wound management applications, notably in dental, cardiovascular, and general surgical procedures. The market is expected to expand at a compound annual growth rate (CAGR) of roughly 6% between 2023 and 2028, reaching USD 215 million by 2028 [1].

Who are the key players and what market shares do they control?

Major manufacturers include:

• Johnson & Johnson (Ethicon)
• Leveg Corporation
• Baxter International
• Pfizer (through subsidiaries)
• CryoLife

Ethicon holds over 60% of the market, primarily due to its early approval and established distribution channels. The remaining share is spread across smaller competitors and regional players. Market concentration remains high, with top three firms controlling more than 85% of global sales.

What are the regulatory and clinical drivers influencing market growth?

Regulatory approvals enable commercialization in various regions:

• U.S. FDA approved the first recombinant thrombin product in 2010.
• European Medicines Agency (EMA) granted approval in 2012.
• Several Asian countries adopted approvals from local regulatory agencies between 2015-2018.

Clinical factors influencing growth include:

• Increasing adoption in minimally invasive surgeries.
• Favorable safety profiles; recombinant form reduces disease transmission risks linked to human or animal-derived thrombin.
• Growing indication breadth, including hemostasis in neurosurgery and gastrointestinal procedures.

What are the main challenges impacting the market’s financial trajectory?

Key obstacles include:

• Pricing pressure: Reimbursement challenges, particularly in cost-sensitive regions.
• Competition from other hemostatic agents: Such as fibrin sealants and collagen-based products.
• Limited awareness and adoption: Especially in emerging markets where traditional topical agents persist.
• Patent expiration and biosimilar entry: Potential erosion of market share for branded products.

How does the pipeline for recombinant thrombin products look?

Current development efforts focus on:

• Extended-release formulations for improved handling.
• Combination products with other hemostatic agents.
• Early-stage research into genetically engineered variants with enhanced potency.

Only a handful of candidates are in late-stage clinical trials as of 2023, reflecting moderate pipeline activity. The majority of pipeline products target niche surgical procedures with unmet needs.

What is the forecasted revenue contribution for recombinant thrombin topical in the coming years?

Based on current adoption trends and pipeline activity, recombinant thrombin topical is projected to generate USD 200-250 million globally by 2028. The North American and European markets will continue to dominate, accounting for about 70% of sales. Emerging markets are expected to increase their share from 15% to 25%, driven by increasing surgical procedures and healthcare infrastructure improvements.

How do pricing and reimbursement policies influence financial outcomes?

Pricing varies widely:

• In the US, prices range from USD 50 to USD 150 per treatment tube.
• In Europe, reimbursement policies vary; some countries cover full costs, while others require patient co-pay.

Price sensitivity, especially in Asian markets, constrains revenue growth. Favorable reimbursement policies can significantly accelerate adoption and revenue, whereas restrictive policies delay market penetration.

What is the overall R&D investment trend for recombinant thrombin topical?

Annual R&D spending is approximately USD 25-30 million, primarily by the leading firms. Investment focuses on improving drug stability, shelf life, and formulating combination products. Early-stage research aims at bioengineered variants with enhanced activity, but overall pipeline activity remains moderate relative to larger biopharma sectors.

---

Key Takeaways

• The recombinant thrombin topical market stands at USD 150 million in 2022, with growth driven by surgical demand.
• Ethicon dominates with over 60% market share; barriers include pricing pressures and competition.
• Regulatory approvals in major markets have facilitated commercialization; pipeline activity remains modest.
• Market expansion depends heavily on reimbursement policies, especially in emerging regions.
• Revenue projections suggest a CAGR of 6%, reaching USD 215 million by 2028, with North America and Europe leading growth.

---

FAQs

Q1: What factors could accelerate market growth for recombinant thrombin topical?
A: Increased adoption in minimally invasive surgeries, expanded indications, favorable reimbursement policies, and pipeline innovations.

Q2: How does recombinant thrombin compare to animal-derived thrombin?
A: Recombinant thrombin reduces disease transmission risk, offers consistent quality, and enjoys regulatory advantages in some regions.

Q3: What are main competitive threats to existing market players?
A: Biosimilar entries post-patent expiration, alternative hemostatic products, and price pressures in emerging markets.

Q4: How significant is the pipeline for future revenue?
A: Moderate; few late-stage candidates aim to expand indications or improve product formulations, but overall pipeline activity remains limited.

Q5: How do regional differences influence market prospects?
A: North America and Europe dominate revenue streams. Asia and Latin America represent growth opportunities due to increasing surgical volumes and healthcare infrastructure development.

---

References

[1] MarketWatch. (2022). "Global Recombinant Thrombin Market Size, Share & Trends." Retrieved from https://www.marketwatch.com